DETERMINATION OF 3-HYDROXY-3-PYRROLINE-2-ONE IN URINE AND STUDY OF ITS EXCRETION FROM THE ORGANISM OF LABORATORY ANIMALS

It is known that almost any disease of the central nervous system is accompanied by the development of cognitive disorders. The drugs of choice in the complex therapy in this case are nootropics. On the world market racetam group, i.e. derivatives of alpha-pyrrolidone, prevails among nootropics, and the derivatives have a wide spectrum of pharmacological activity. Currently, this group continues to expand. By the employees of Perm State Pharmaceutical Academy (PSPA), ruled by Professor V.L. Gein, a new biologically active compound, a 3-pyrrolin-2-one derivative KOH-1 was synthesized. This compound is at the preclinical research stage now.

The aim of this work was the development of methods for determination of KOH-1 in urine by high performance liquid chromatography (HPLC), the study of excretion KOH-1 from the organism of laboratory animals.

Materials and methods. Studies on the development of methods were carried out by using a liquid chromatograph LC-20 Prominence (Shimadzu, Japan) with a diode-array detector. The validation was carried out in accordance with the requirements for bioanalytical methods, in terms of selectivity, linearity, precision and accuracy. The study of excretion of KOH-1 was performed on white non-linear male rats weighing 300-400 g. The substance KOH-1 was administered once orally in a suspension of starch mucus at a dose of 100 mg/kg.

Results and discussion. As a result of the research, the  method for determining the biologically active compound KOH-1 in urine has been developed. The validation showed its suitability for pharmacokinetic studies. The data on daily excretion of KOH-1 in urine after a single oral administration to rats were obtained.

Conclusion. The developed conditions for the chromatographic determination of KOH-1 in urine can be used in pharmacokinetic studies, both at the preclinical and clinical stages of the study of a potential drug. The data on excretion of KOH-1 will allow to determine the ways of excretion of the preparation, and also to select a rational dosage, to identify possible contraindications to the use.

1. Ushkalova E.A., Ushkalova A.V. FARMAKOTERAPIJA KOGNITIVNYH NARUSHENIJ RAZLICHNOGO GENEZA: SOVREMENNOE SOSTOJANIE I PERSPEKTIVNYE NAPRAVLENIJA [PHARMACOTHERAPY OF COGNITIVE DISTURBANCES OF VARIOUS GENESIS: MODERN STATE AND PERSPECTIVE DIRECTIONS]. RMZh [RMJ]. 2014. N 22. P.1613. (In Russ.)

2. Shuklina N.S., Kolla V.Je. ANTIAMNESTICHESKOE DEJSTVIE PROIZVODNYH RJADA 3-GIDROKSI-3PIRROLIN-2-ONA [ANTIAMINETIC ACTION OF THE DERIVATIVES OF 3-HYDROXY-3-PYRROLIN-2ONE]. Jeksperimental’naja i klinicheskaja farmakologija. [Experimental and clinical pharmacology]. 2003. V. 66. N 6. P. 12–15. (In Russ.)

3. Men’shikova L.A., Pechenkina I.G., Bereza N.S. OSOBENNOSTI DOKLINICHESKIH ISSLEDOVANIJ INNOVACIONNYH LEKARSTVENNYH PREPARATOV (KOROTKOE SOOBSHHENIE) [PECULIARITIES OF PRECLINICAL RESEARCH OF INNOVATIVE DRUGS (SHORT MESSAGE)]. Nauchno-proizvodstv. zh-l. Razrabotka i registracija LS [Scientific production. Journal. Development and registration of drugs]. 2013. N 2 (2). URL: http://pharmjournal.ru/articles/stati/osobennosti-doklinicheskix-issledovanij-innovaczionnyix-lekarstvennyix-preparatov-korotkoe-soobshhenie (access data: 27.12.2016) (In Russ.)

4. Antnova M.I., Prokopov A.A, Ahapkina V.I., Berljand A.S. KOLICHESTVENNYJ ANALIZ FENOTROPILA V BIOLOGICHESKIH OB’EKTAH METODOM GAZOZHIDKOSTNOJ HROMATOGRAFII [QUANTITATIVE ANALYSIS OF PHENOTROPILE IN BIOLOGICAL OBJECTS BY THE METHOD OF GAS-LIQUID CHROMATOGRAPHY] // Him.-farm. zhurn. [Chem.-pharm. journal]. 2003. N 10. P. 46–47. (In Russ.)

5. Simpson RC, Boppana VK, Hwang BY, Rhodes GR. DETERMINATION OF OXIRACETAM IN HUMAN PLASMA BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH FLUORIMETRIC DETECTION. Journal of Chromatography. 1993. N 631 (1-2). P. 227–232.

6. Zhang J, Liang J, Tian Y, Zhang Z, Chen Y. SENSITIVE AND SELECTIVE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD FOR THE QUANTIFICATION OF ANIRACETAM IN HUMAN PLASMA. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007. N 858 (1-2). P. 129–134. DOI: 10.1016/j.jchromb.2007.08.010

7. Tian Y, Zhang JJ, Feng SD, Zhang ZJ, Chen Y. PHARMACOKINETICS AND BIOEQUIVALENCE STUDY OF ANIRACETAM AFTER SINGLE-DOSE ADMINISTRATION IN HEALTHY CHINESE MALE VOLUNTEERS. Arzneimittel – Forschung. 2008. 58(10). P. 497–500. DOI: 10.1055/s-0031-1296547.

8. Cai S., Wang L. DETERMINATION OF ANIRACETAM’S MAIN METABOLITE, N-ANISOYL-GABA, IN HUMAN PLASMA BY LC-MS/MS AND ITS APPLICATION TO A PHARMACOKINETIC STUDY. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012. 897. P. 50–54. DOI: 10.1016/j.jchromb.2012.04.007

9. Zhang Q Yang W, Yang Y, Xing H, Zhang Q, Li J, Lu Y, He J, Yang S, Zhao D, Chen X. Comparative pharmacokinetic studies of racemic oxiracetam and its pure enantiomers after oral administration in rats by a stereoselective HPLC method . Journal of pharmaceutical and biomedical analysis. 2015. 111. P. 153–158. DOI: 10.1016/j.jpba.2015.03.039

10. Son J, Lee J, Lee M, Lee E, Lee JH, La S, Kim DH. RAPID QUANTITATIVE ANALYSIS OF OXIRACETAM IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY/ELECTROSPRAY TANDEM MASS SPECTROMETRY. Journal of pharmaceutical and biomedical analysis. 2004. No. 36 (1). P. 183–187. DOI: 10.1016/j.jpba.2004.05.010

11. Wan X, Wang H, Ma P, Xi L, Sun J, He Z, Zhang X, Liu X. SIMULTANEOUS DETERMINATION OF OXIRACETAM AND ITS DEGRADED SUBSTANCE IN RAT PLASMA BY HPLC-MS/MS AND ITS APPLICATION TO PHARMACOKINETIC STUDY AFTER A SINGLE HIGH-DOSE INTRAVENOUS ADMINISTRATION. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2014. 969. P. 95–100. DOI: 10.1016/j.jchromb.2014.07.041

12. Wang X, Zhu J, Xu R, Yang X, Wu H, Lin D, Ye F, Hu L. Determination of piracetam in rat plasma by LC-MS/ MS and its application to pharmacokinetics. Biomedical Chromatography. 2010. 24(10). P. 1108–1112. DOI: 10.1002/bmc.1412.

13. Prokopov A.A., Kotlova L.I., Berljand A.S. IZUCHENIE JEKSKRECII TETRAMEZINA U KRYS RATS [STUDY OF EXCRETION OF PREPARATION OF PHENOTROPIL FROM THE ORGANISM OF]. Him.farm.zhurn. [Chemical-farm. Journal]. 2006. V. 40. N 3. P. 7–9. (In Russ.)

14. Prokopov A.A., Kostebelov N.V., Berljand A.S. IZUCHENIE JEKSKRECII AL’BIKARA IZ ORGANIZMA KRYS [STUDY OF ALBIKAR EXCRETION FROM THE ORGANISM OF RATS]. Him.-farm. zhurn. [Chemical-farm. journal]. 2002. V. 36. N 4. P. 7–9. (in Russ.)

15. Antonova M.I., Prokopov A.A, Ahapkina V.I., Berljand A.S. IZUCHENIE JEKSKRECII PREPARATA FENOTROPIL IZ ORGANIZMA KRYS [STUDY OF EXCRETION OF PREPARATION OF PHENOTROPIL FROM THE ORGANISM OF RATS]. Him.-farm. zhurn. [Chemical-farm. journal]. 2004. V. 38. N 11. P. 6–7. (in Russ.)

16. Farhan A.S., Nawab S., Nighat S., Alisha W.S., Ahmad M., Mehjebeen, Naseem H. DEVELOPMENT OF NEW METHOD FOR SIMULTANEOUS ANALYSIS OF PIRACETAM AND LEVETIRACETAM IN PHARMACEUTICALS AND BIOLOGICAL FLUIDS: APPLICATION IN STABILITY STUDIES. BioMed Research International. 2014. Vol. 2014. Article ID 758283, 8 pages. DOI:10.1155/2014/758283

17. Bulgakova E.A., Karpenko Ju.N. VYBOR OPTIMAL’NYH USLOVIJ IZVLECHENIJA BIOLOGICHESKI AKTIVNYH PROIZVODNYH 3-PIRROLIN-2-ONA IZ MOCHA [THE CHOICE OF OPTIMAL CONDITIONS OF EXTRACTION OF BIOLOGICALLY ACTIVE DERIVATIVES OF 3-PYRROLIN-2-SHE FROM URINE]. Innovacionnaja nauka: mezhdunarodnyj nauchnyj zhurnal [Innovative science: an international scientific journal]. Ufa, 2015. N 4/2015. Ch. 3. P. 135–138. (in Russ.)

18. Kljasheva O.N., Jarygina T.I., Gejn V.L., Odegova T.F., Sattarova O.E., Karpenko Ju.N. Razrabotka metodov ocenki kachestva substancii novogo biologicheski aktivnogo soedinenija KON-1 [DEVELOPMENT OF METHODS OF ESTIMATION OF THE QUALITY OF THE SUBSTANCE OF THE NEW BIOLOGICALLY ACTIVE CONNECTION OF CON-1]. Farmacija [Pharmacy]. Moskva, 2012. N 5. P. 8–10. (in Russ.)

19. Guidance for Industry: Bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER). U.S. Government Printing Office. Washington, DC, 2001. 25 p.

20. Guideline on validation of bioanalytical methods (draft). European Medicines Agency. Committee for medicinal products for human use. London, 2009. 23 p.

21. Reshenie Soveta Evrazijskoj jekonomicheskoj komissii ot 03.11.2016 № 85 «Ob utverzhdenii Pravil provedenija issledovanij biojekvivalentnosti lekarstvennyh preparatov v ramkah Evrazijskogo jekonomicheskogo sojuza». [Decision of the Council of the Eurasian Economic Commission of 03.11.2016 No. 85 “On the Approval of the Rules for Conducting Studies on the Bioequivalence of Medicinal Products within the Framework of the Eurasian Economic Union”]. 2016. 57 p. (in Russ.)

22. Manturov D.S., Karpenko Ju.N., Jarygina T.I. Razrabotka uslovij opredelenija biologicheski aktivnogo soedinenija VKV-1 metodom VJeZhH dlja farmakokineticheskih issledovanij [Development of conditions for the determination of the biologically active compound BKV-1 by HPLC for pharmacokinetic studies]. Razrabotka, issledovanie i marketing novoj farmacevticheskoj produkcii: sb. nauch. tr. [Development, research and marketing of new pharmaceutical products: Sat. sci. tr.] / Pjatigorskaja gosudarstvennaja farmacevticheskaja akademija [Pyatigorsk State Pharmaceutical Academy]. Pyatigorsk, 2012. V. 67. P. 250–253. (in Russ.)

23. Ob utverzhdenii Pravil laboratornoj praktiki: prikaz Ministerstva zdravoohranenija i social’nogo razvitija Rossijskoj Federacii ot 23 avgusta 2010 g. №708-n [On the approval of the Rules of laboratory practice: the order of the Ministry of Health and Social Development of the Russian Federation of August 23, 2010 № 708-n]. URL: http://www.consultant.ru/document/cons_doc_LAW_105953/ (access data: 11.01.2017). (in Russ.)